![1]()
News
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
June 16, 2020
In the landmark DAPA-HF trial that enrolled HFrEF patients without diabetes, treatment with dapagliflozin cut incident type 2 diabetes by a relative 32%.
![1]()
News
For COVID-19 plus diabetes, glycemic control tops treatment list
June 15, 2020
Tight glucose control led to better results in patients with diabetes and COVID-19.
News
Half of type 1 diabetes patients with COVID-19 manage at home
June 12, 2020
Despite high rates of hyperglycemia and DKA, only about half of patients with type 1 diabetes and COVID-19 required hospitalization, according to data from the T1D Exchange; mortality was low.
News
10% with diabetes hospitalized for COVID-19 die within a week
June 1, 2020
“Even in diabetes, each increase in BMI is associated with an increase in the risk of intubation and/or death in the 7 days following admission for COVID-19.”
News
‘The story unfolding is worrisome’ for diabetes and COVID-19
May 28, 2020
Diabetes Care has published a host of new articles on diabetes and COVID-19 infection, as NIDDK researchers also acknowledge risks to other organ systems from the SARS-CoV-2 virus.
Opinion
Seek safe strategies to diagnose gestational diabetes during pandemic
May 27, 2020
Professional societies in the U.K., Canada, and Australia offer guidance to reduce risk while testing pregnant women for gestational diabetes during pandemic.
News
Glucose control linked to COVID-19 outcomes in largest-yet study
May 15, 2020
Wuhan researchers found preexisting type 2 diabetes worsened prognosis of COVID-19; but those whose glucose stayed “in-range” had better outcomes.
News
More guidance on inpatient management of blood glucose in COVID-19
May 7, 2020
Diabetes UK’s COVID-19 task force addresses inpatient use of subcutaneous insulin for managing hyperglycemia and ketoacidosis when IVs are unavailable.
News
FDA approves dapagliflozin for low-EF heart failure
May 7, 2020
The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.
News
New study of diabetes drug for COVID-19 raises eyebrows
May 1, 2020
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
